- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00353483
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
March 15, 2024 updated by: Washington University School of Medicine
The main purpose of this study is to compare genetic markers present on tumor cells before and after chemotherapy.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
In this study, the investigators propose that persistent disseminated tumor cells (DTC) present after systemic therapy represent a unique subpopulation of all DTC, are predictors of a poor response to systemic therapy and correlate with poor clinical outcome.
The investigators hypothesize that systemic therapy-resistant DTC can be identified by their expression of a unique constellation of tumor marker proteins which may be similar to those expressed by breast cancer stem cells.
In this research, the investigators' specific aims are : 1) to characterize tumor markers expressed by DTC which are present after systemic therapy, 2) to compare the expression of these markers to that on DTC detected prior to systemic therapy, 3) to correlate expression of the defined tumor markers on DTC with clinical outcome of breast cancer patients to identify those markers that are predictive of disease recurrence, 4) to utilize biomarkers identified in Specific Aims 1 and 2 to isolate purified DTC for further molecular analysis.
Study Type
Observational
Enrollment (Estimated)
300
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rebecca Aft, MD, PhD
- Phone Number: 314-747-0063
- Email: aftr@wustl.edu
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63119
- Recruiting
- Washington University School of Medicine
-
Contact:
- Tracey Guthrie
- Phone Number: 314-747-4404
- Email: guthriet@wustl.edu
-
Sub-Investigator:
- Haeseong Park, MD
-
Contact:
- Rebecca Aft, MD, PhD
- Phone Number: 314-747-0063
- Email: aftr@wustl.edu
-
Sub-Investigator:
- Mark Watson, MD, PhD
-
Sub-Investigator:
- William Gillanders, MD
-
Sub-Investigator:
- Timothy Eberlein, MD
-
Sub-Investigator:
- Katherine Weilbaecher, MD
-
Sub-Investigator:
- Michael Naughton, MD
-
Sub-Investigator:
- Shunqiang Li, MD
-
Sub-Investigator:
- Julie Margenthaler, MD
-
Sub-Investigator:
- Cynthia Ma, MD
-
Sub-Investigator:
- Katherine Glover-Collins, MD, PhD
-
Sub-Investigator:
- Caron Rigden, MD
-
Sub-Investigator:
- Rama Suresh, MD
-
Sub-Investigator:
- Gregory Longmore, MD
-
Sub-Investigator:
- Ashley Frith, MD
-
Sub-Investigator:
- Foluso Ademuyiwa, MD
-
Sub-Investigator:
- Peter Oppelt, MD
-
Sub-Investigator:
- Ron Bose, MD, PhD
-
Sub-Investigator:
- Leonel Hernandez Aya, MD
-
Sub-Investigator:
- Mathew Cherian, MD
-
Sub-Investigator:
- Lindsay Peterson, MD
-
Sub-Investigator:
- Cara Cipriano, MD
-
Principal Investigator:
- Rebecca Aft, MD, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients seen in clinic at Washington University School of Medicine.
Description
Inclusion Criteria:
- Recently diagnosed with clinical stage II, III, or IV breast cancer
- Planning to undergo neoadjuvant or adjuvant systemic therapy; patients who have already completed neoadjuvant systemic therapy are also eligible
- Must be >= 18 years of age
- If female, must not be pregnant
- Must not have Hepatitis B, C, or HIV
- Must be willing and able to sign informed consent document
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Tissue, blood, and bone marrow (optional) collection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Characterize tumor markers expressed by DTC which are present after systemic therapy
Time Frame: Approximately 6 years
|
Approximately 6 years
|
Compare the expression of these markers to that on DTC detected prior to systemic therapy
Time Frame: Approximately 6 years
|
Approximately 6 years
|
Correlate expression of the defined tumor markers on DTC with clinical outcome of breast cancer patients to identify those markers that are predictive of disease recurrence.
Time Frame: Approximately 6 years
|
Approximately 6 years
|
Compare the tumor markers present on DTC before and after chemotherapy with the tumor marker expression of the primary tumor and post-treatment tumor.
Time Frame: Approximately 6 years.
|
Approximately 6 years.
|
To xenograft tumor cells into mice for further genetic and phenotypic characterization.
Time Frame: Approximately 6 years
|
Approximately 6 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Rebecca Aft, M.D., Ph.D., Washington University School of Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Diel IJ, Cote RJ. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer. Cancer Treat Rev. 2000 Feb;26(1):53-65. doi: 10.1053/ctrv.1999.0150.
- Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 2000 Feb 24;342(8):525-33. doi: 10.1056/NEJM200002243420801. Erratum In: N Engl J Med 2000 Jul 27;343(4):308.
- Braun S, Naume B. Circulating and disseminated tumor cells. J Clin Oncol. 2005 Mar 10;23(8):1623-6. doi: 10.1200/JCO.2005.10.073. No abstract available.
- Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, Sommer H, Pantel K, Gerber B, Friese K. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer. 2005 Mar 1;103(5):884-91. doi: 10.1002/cncr.20834.
- Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH, Riethmuller G. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet. 2002 Aug 31;360(9334):683-9. doi: 10.1016/S0140-6736(02)09838-0.
- Choesmel V, Pierga JY, Nos C, Vincent-Salomon A, Sigal-Zafrani B, Thiery JP, Blin N. Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance. Breast Cancer Res. 2004;6(5):R556-70. doi: 10.1186/bcr898. Epub 2004 Jul 29.
- Lesurf R, Griffith OL, Griffith M, Hundal J, Trani L, Watson MA, Aft R, Ellis MJ, Ota D, Suman VJ, Meric-Bernstam F, Leitch AM, Boughey JC, Unzeitig G, Buzdar AU, Hunt KK, Mardis ER. Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial. Ann Oncol. 2017 May 1;28(5):1070-1077. doi: 10.1093/annonc/mdx048.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 14, 2005
Primary Completion (Estimated)
August 31, 2025
Study Completion (Estimated)
August 31, 2025
Study Registration Dates
First Submitted
July 17, 2006
First Submitted That Met QC Criteria
July 17, 2006
First Posted (Estimated)
July 18, 2006
Study Record Updates
Last Update Posted (Actual)
March 18, 2024
Last Update Submitted That Met QC Criteria
March 15, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 05-0648 / 201101961
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasms
-
Emory UniversityEisai Inc.TerminatedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Tumors, BreastUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Seagen Inc.CompletedTriple Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms | HER2 Positive Breast Neoplasms | HER2 Mutations Breast NeoplasmsUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Providence Health & ServicesBrooklyn ImmunoTherapeutics, LLCActive, not recruitingBreast Neoplasm | Triple Negative Breast Cancer | Breast Neoplasm, MaleUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Celgene CorporationTerminatedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLCCompletedMale Breast Cancer | Breast - FemaleUnited States
-
GlaxoSmithKlineCompletedMetastatic Breast Cancer | Neoplasms, BreastJapan
Clinical Trials on Bone marrow biopsy
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid System NeoplasmUnited States
-
Postgraduate Institute of Medical Education and...Completed
-
Medical College of WisconsinRecruitingBone Marrow Biopsy ProcedureUnited States
-
Duke UniversitySuspendedKidney Cancer | Prostate Cancer | Bladder Cancer | Genito Urinary CancerUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI); Incuron LLCRecruitingRefractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Recurrent Osteosarcoma | Refractory Osteosarcoma | Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent Diffuse Intrinsic Pontine Glioma | Metastatic Malignant Neoplasm in the Central... and other conditionsUnited States
-
Vidacare CorporationCompletedBone Marrow Aspiration and Biopsy Specimen CollectionUnited States
-
Vidacare CorporationCompletedBone Marrow Biopsy ProceduresUnited States, Spain
-
Assiut UniversityNot yet recruiting
-
Melissa BatesDepartment of Health and Human ServicesRecruitingMultiple Myeloma | Monoclonal Gammopathy of Undetermined SignificanceUnited States
-
University of Michigan Rogel Cancer CenterTerminatedMetastatic Breast CancerUnited States